PAREXEL International Corporation, a global biopharmaceutical services provider, has signed a services agreement with Pfizer Inc. Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed.
“PAREXEL will continue to leverage its proven clinical processes and expertise to help Pfizer conduct clinical trials and accomplish its drug development goals,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International. “Our team is focused on applying dynamic and innovative operational models to help Pfizer develop drugs to improve health and treat diseases for patients around the world.”
As an innovator in creating strategic partnerships in the biopharmaceutical services industry, PAREXEL uses a spectrum of relationship models to meet the diverse requirements of clients. This includes large companies as well as emerging companies through its BioPharm unit. PAREXEL’s approach focuses on assisting biopharmaceutical companies in reducing fixed costs, shortening development times, and speeding delivery of safe and effective treatments to market. PAREXEL has transformed its business to deliver a new level of strategic services based on program design expertise, operational excellence, and project leadership to help clients achieve their development goals.